Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

2311 results about "Acetylation" patented technology

Acetylation (or in IUPAC nomenclature ethanoylation) describes a reaction that introduces an acetyl functional group into a chemical compound. Deacetylation is the removal of an acetyl group. Acetylation refers to the process of introducing an acetyl group (resulting in an acetoxy group) into a compound, namely the substitution of an acetyl group for an active hydrogen atom. A reaction involving the replacement of the hydrogen atom of a hydroxyl group with an acetyl group (CH₃CO) yields a specific ester, the acetate. Acetic anhydride is commonly used as an acetylating agent reacting with free hydroxyl groups. For example, it is used in the synthesis of aspirin, heroin, and THC-O-acetate.

Multivalent pneumococcal polysaccharide-protein conjugate composition

An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Also described is a method for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 1 polysaccharide covalently linked to a carrier protein, the method including partial de-O-acetylation of the polysaccharide by mild hydrolysis in an alkaline pH buffer.
Owner:WYETH LLC

Process for the production of esters from alcohols using acetic acid as acetylating and clays as catalysts

The present invention relates to a process for the preparation of esters from alcohols using acetic acid as acetylating agent and clays as catalysts, which comprises the preparation of esters in a single step from the reaction of aliphatic, acyclic, cyclic, heterocyclic, alpha,beta-unsaturated and aromatic alcohols with carbon atoms in the range of C1 to C10 with acetic acid in a molar ratio of 1:3 to 11 using reusable natural montmorillonite / metal ion-exchanged clay catalysts in the solvent medium of aliphatic, aromatic, or chlorinated hydrocarbons at 30-140° C. for a period in the range of 0.02 to 3.0 hrs, and recovering the corresponding esters by simple work-up procedure.
Owner:COUNCIL OF SCI & IND RES

Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for treatment of certain cancers

The invention relates to the use of monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of said antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, said antibody or said fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. The invention also relates to artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.
Owner:UNIV DE NANTES

Proteome epitope tags and methods of use thereof in protein modification analysis

Disclosed are reagents and methods for reliably detecting the presence and measuring the amount of proteins, including proteins with various post-translational modifications (phosphorylation, glycosylation, methylation, acetylation, etc.) in a sample by the use of one or more capture agents that recognize and interact with recognition sequences uniquely characteristic of a protein or a set of proteins (Proteome Epitope Tags, or PETs) in the sample. Arrays comprising these capture agents or PETs are also provided.
Owner:EPITOME BIOSYST

Histone deacetylase inhibitors and cognitive applications

InactiveUS20060018921A1Enhances long-term passive avoidance memoryImprove long-termBiocideNervous disorderAcetylationPoor memory
The present invention relates to the enhancement of cognition in an individual by delivery of a histone acetylation regulator, such as a histone deacetylase inhibitor. The individual may have normal or poor memory, and the poor memory may be the result of a pathogenic condition or a non-pathogenic condition, such as with normal aging-related impairment. In a specific embodiment, enhancement of cognition occurs in an individual having a mental retardation syndrome.
Owner:BAYLOR COLLEGE OF MEDICINE

Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779

Methods for the synthesis of CCI-779 and proline-CCI-779 are described, including a method involving lipase-catalyzed acetylation of 42-hydroxy of rapamycin with a vinyl ester of 2,2-bis(hydroxymethyl) propionic acid in an organic solvent followed by deprotection. Also provided are products containing proline-CCI-779 and uses thereof.
Owner:WYETH LLC

Laminated glass intermediate film and laminated glass

The present invention provides an intermediate film for laminated glass which can improve the sound-insulating property. The intermediate film for laminated glass according to the present invention has a layered structure including at least two layers, comprising: a first layer containing a polyvinyl acetal resin and a plasticizer; and a second layer positioned on a first surface of the first layer. In a phase diagram of three values including a degree of acetalization, a degree of acetylation, and a hydroxy group content of the polyvinyl acetal resin contained in the first layer, the values of the degree of acetalization, the degree of acetylation, and the hydroxy group content each fall within a region surrounded by a line including four straight lines connecting a first coordinate (degree of acetalization:degree of acetylation:hydroxy group content=70 mol %:30 mol %:0 mol %), a second coordinate (degree of acetalization:degree of acetylation:hydroxy group content=34 mol %:30 mol %:36 mol %), a third coordinate (degree of acetalization:degree of acetylation:hydroxy group content=94 mol %:0 mol %:6 mol %), and a fourth coordinate (degree of acetalization:degree of acetylation:hydroxy group content=100 mol %:0 mol %:0 mol %) in the stated order.
Owner:SEKISUI CHEM CO LTD

Injectable chitosan mixtures forming hydrogels

ActiveUS20130244972A1Degree of control over variousCosmetic preparationsBiocideAcetylationPolysaccharide
A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., that includes at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.
Owner:CHI2GEL LTD

Industrial process for the synthesis of 17a-acetoxy-11ss-[4-(n,n-dimethyl-amino)- phenyl]-19-norpregna-4,9-diene-3,20-dione and new intermediates of the process

The present invention relates to a new industrial process for the synthesis of solvate- free 17a-acetoxy-11ss-[4-(N,N-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione [CDB -2914] of formula (I) which is a strong antiprogestogene and antiglucocorticoid agent. The invention also relates to compounds of formula (VII) and (VIII) used as intermediates in the process. The process according to the invention is the following: i) 3-(ethylene-dioxy)-estra-5(10),9(11)-diene-17-one of formula (X) is reacted with potassium acetilyde formed in situ in dry tetrahydrofuran by known method, ii) the obtained 3-(ethylene-dioxy)-17a-ethynyl-17ss-hydroxy-estra-5(10),9(11)-diene of formula (IX) is reacted with phenylsulfenyl chloride in dichloromethane in the presence of triethylamine and acetic acid, iii) the obtained isomeric mixture of 3-(ethylene-dioxy)-21-(phenyl-sulfinyl)-19-norpregna-5(10),9(11),17(20),20-tetraene of formula (VIII) is reacted first with sodium methoxide in methanol, then with trimethyl phosphite, iv) the obtained 3-(ethylene-dioxy)-17a-hydroxy-20-methoxy-19-norpregna-5(10),9(11),20-triene of formula (VII) is reacted with hydrogen chloride in methanol, then v) the obtained 3-(ethylene-dioxy)-17a-hydroxy-19-norpregna-5(10),9(11l); -diene-20- one of formula (VI) is reacted with ethylene glycol hi dichloromethane in the presence of trimethyl orthoformate and p-toluenesulfonic acid by known method, vi) the obtained 3,3,20,20-bis(ethylene-dioxy)-17a-hydroxy-19-norpregna- 5(10),9(11)-diene of formula (V) is reacted with hydrogen peroxide in a mixture of pyridine and dichloromethane in the presence of hexachloroacetone by known method, vii) the obtained 3,3,20,20-bis(ethylene-dioxy)-17a-hydroxy-5,10-epoxy-19-norpregn-9(11)-ene of formula (IV), containing approximately a 1:1 mixture of 5a,10a- and 5ss,10ss-epoxides, is isolated from the solution and reacted with a Grignard reagent obtained from 4-bromo-N,N-dimethyl-aniline in tetrahydrofuran.
Owner:RICHTER GEDEON NYRT

Compositions comprising phenyl-glycine derivatives

The invention relates to compositions and methods useful for treating a variety of cosmetic conditions and dermatological disorders, where the composition includes a phenyl glycine derivative represented by the following formula:wherein, R1 and R2 are independently H, I, F, Cl, Br, OH, SH, NH2, NHNH2, alkyl, aralkyl, alkoxy, acetoxy, acyloxy group having 1 to 9 carbon atoms, and being attached at the 2, 3 or 4 position of the phenyl group, whereby when R1 and / or R2 are OH, SH, NH2, they may be acetylated or acylated with 1 to 9 carbon atoms; R3 is H, formyl, acetyl, propanoyl, acyl, alkyl, aralkyl or an aryl group having 1 to 9 carbon atoms; R4 is OH, NH2, NHOH, NHNH2, or OR; where R is an alkyl, aralkyl or aryl group having 1 to 9 carbon atoms; the H attached to any carbon or nitrogen atom may be substituted by I, F, Cl, Br, OH, SH, NH2, NHNH2, an alkyl, aralkyl, alkoxy or acyl group having 1 to 9 carbon atoms. Phenyl-glycine and its derivatives may be present as isomeric D or L, non-isomeric or racemic DL, as a free acid, salt, lactone, amide or ester form.
Owner:YU RUEY J +1

Coloring substance composition and a method of manufacturing same

A composition comprising coloring substance bodies that are at least partially coated with beet pectin, chicory pectin and / or Jerusalem artichoke pectin or other pectin types having a high degree of acetylation. The composition which may be water dispersible is useful for preparation of health improving products and / or coloring products for use in the coloring of edible products including food products and nutraceuticals, and for coloring of pharmaceutical products.
Owner:CHR HANSEN NATURAL COLORS

Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies

The invention provides a method for effecting the trans-differentiation of a somatic cell, i.e., the conversion of a somatic cell of one cell type into a somatic cell of a different cell type. The method is practiced by culturing a somatic cell in the presence of at least one agent selected from the group consisting of (a) cytoskeletal inhibitors and (b) inhibitors of acetylation, and (c) inhibitors of methylation, and also culturing the cell in the presence of agents or conditions that induce differentiation to a different cell type. The method is useful for producing histocompatible cells for cell therapy.
Owner:ADVANCED CELL TECH INC

Assay for measuring acetylation or deacetylation activity of an enzyme

This invention is directed to a continuous method for measuring the activity of an enzyme that catalyzes the addition of an acetyl group to a residue capable of being acetylated or an enzyme that catalyzes the removal of an acetyl group from an acetylated residue. In particular the present invention is directed to a continuous method for measuring the activity of histone acetyltranferases and histone deacetylase enzymes.
Owner:PHARMACYCLICS

Process for purification of sucralose

The present invention relates to a process for the purification of Sucralose of formula (I) which comprises acetylation of substantially impure Sucralose to its penultimate intermediate 4,1',6'-trichloro-4,1',6'-trideoxy galactosucrose penta-acetate (TOPSA) of formula (VI) followed by purification of TOPSA and then deacetylation of purified TOPSA.
Owner:ALEMBIC LTD

Methods for identifying agents which alter histone protein acetylation, decrease aging, increase lifespan

InactiveUS20030207325A1Extend your lifeEasy to identifyCompound screeningSenses disorderADPRibosylationNad dependent
Abstract of the Disclosure Methods of identifying agents which alter the NAD-dependent acetylation status and mono-ADP-ribosylation of nuclear proteins are disclosed. The methods further include identifying agents which alter the life span or aging of a cell or an organism by determining the level of NAD-dependent acetylation and / or ADP ribosylation of a nuclear protein. The invention also relates to a mammalian Sir2 protein which acetylates or deacetylates nuclear proteins in a NAD-dependent manner and has mono-ADP-ribosyltransferase activity. Host cells producing the Sir2 protein and antibodies to the Sir2 protein are also provided.
Owner:MASSACHUSETTS INST OF TECH

Method of identifying active chromatin domains

The invention provides a method of mapping DNA-protein interactions within a genome by fixing living cells to cross-link DNA and proteins, lysing the cells, and isolating chromatin by immunoprecipitation. DNA is purified and a SAGE protocol is performed on the purified DNA to produce GMAT-tag sequences, which are compared to a genomic sequence of the living cells to map DNA-protein interactions. The invention further provides a method of identifying an active chromatin domain and a method of identifying aberrant chromatin acetylation, wherein chromatin immunoprecipitation is performed using an antibody recognizing acetylated histone protein.
Owner:GOVERNMENT OF THE US REPRESENTED BY THE SEC

Method for producing stem cells with increased developmental potential

InactiveUS20060084172A1Increased differentiation potentialHigh development potentialGenetic material ingredientsGenetically modified cellsBiological bodyTissue sample
The invention relates to a method for producing stem cells having an increased development potential from somatic stem cells, wherein a tissue sample comprising somatic stem cells or a body fluid sample comprising somatic stem cells is taken from an organism, wherein from this tissue sample or body fluid sample as an option somatic stem cells are isolated and / or cultivated, and wherein the thus obtained somatic stem cells are treated with a substance modulating the methylation of the DNA of the cells or a substance modulating the acetylation of chromatin of the cells.
Owner:JULIUS MAXIMILIANS UNIV WURZBURG

Rifamycin analogs and uses thereof

The present invention features rifamycin analogs that can be used as therapeutics for treating or preventing a variety of microbial infections. In one form, the analogs are acetylated at the 25-position, as is rifamycin. In another form, the analogs are deacetylated at the 25-position. In yet other forms, benzoxazinorifamycin, benzthiazinorifamycin, and benzdiazinorifamycin analogs are derivatized at various positions of the benzene ring, including 3′-hydroxy analogs, 4′-and / or 6′ halo and / or alkoxy analogs, and various 5′ substituents that incorporate a cyclic amine moiety.
Owner:ACTIVBIOTICS PHARMA

Novel injectable chitosan mixtures forming hydrogels

ActiveUS20090004276A1Degree of control over variousCosmetic preparationsBiocideAcetylationPolysaccharide
A chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of acetylation in the range of from about 30% to about 60%, and at least one type of chitosan having a degree of deacetylation of at least about 70% is disclosed. Further disclosed is a chitosan composition which forms a hydrogel at near physiological pH and 37° C., comprising at least one type of chitosan having a degree of deacetylation of at least about 70% and a molecular weight of from 10-4000 kDa, and at least one type of a chitosan having a molecular weight of from 200-20000 Da. Further disclosed are methods of preparation and uses of the chitosan compositions.
Owner:CHI2GEL LTD

Preserving compositions containing chitosan and processes for making water soluble O-acetylated chitosan and chitosan

The present invention is directed to a pharmaceutical preserving composition comprising: (a) at least one chitosan or chitosan derivative and (b) at least one buffer solution, as well as methods of preserving contact lens solutions and disinfecting contact lens using such composition. The present invention is further directed to a method of preparing O-acetylated chitosan or chitosan derivatives comprising the steps of dissolving the chitosan or chitosan derivative into an aqueous acidic solution and reacting the chitosan or chitosan derivative with an acetylating agent in the presence of a phase transfer reagent.
Owner:TECH RESOURCE INT

Diacetyl epoxy glyceryl oleates and synthesis method thereof

The invention discloses diacetyl epoxy glyceryl oleates. The general formula of the diacetyl epoxy glyceryl oleates may be (I) or (II). The diacetyl epoxy glyceryl oleates are more stable and flowable than epoxidized soybean oil, the molecular weight of the diacetyl epoxy glyceryl oleates is low, and the diacetyl epoxy glyceryl oleates have high compatibility with polyvinyl chloride (PVC) and arehigh-performance nontoxic plastic plasticizer. The invention also discloses a method for synthesizing diacetyl epoxy glyceryl oleates by starting from oleic acid, which comprises: performing ester exchange of oleic acid and glycerol in the presence of a catalyst to obtain monooleins; compounding monooleins with acetyl to obtain diacetyl monooleins; and performing an epoxidation reaction in an environment with formic acid and hydrogen peroxide, and thus synthesizing diacetyl epoxy glyceryl oleates.
Owner:NANTONG HAIERMA TECH CO LTD

Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation

Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation / N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerizazion.
Owner:ORESTE PASQUA +1

5- or 6-substited naphthoyl imines compounds and antineoplastic application

The invention relates to a 5-site or 6-site substituent naphthalimide compound and antitumor applications thereof, which belongs to the fine chemical field. The compound is characterized in that various aliphatic amidogen, heterocyclic amidogen, aryl and Ar aryl are respectively introduced into the 5-site or 6-site of the naphthalimide by a nucleophilic substitution reaction to obtain small molecule compound similar to a lead compound amonafide structure. The small molecule compound has obvious inhibiting activity in vitro test on Hela and P388D1, and wherein, some compounds have stronger cytotoxicity than the amonafide under the same test conditions. In addition, the structures of the compounds take on diversity; the compounds without acetylation sites can be prevented from having the side effect similar to the amonafide; the other compounds with the acetylation sites can be prevented from having the side effect by personalized administration, therefore, the compound has medical application prospect in curing diseases related to tumors.
Owner:DALIAN UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products